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Abstract
Objectives There are varying reports on whether mono-
clonal gammopathy of undetermined significance-associ-
ated neuropathy (MGUSN) patients are distinguishable
from those with chronic inflammatory demyelinating pol-
yneuropathy (CIDP) and whether specific MGUSN sub-
classes are associated with specific clinical phenotypes.
Methods We performed a retrospective chart review of
MGUSN (n = 56) and CIDP (n = 67) patients. Data
extracted included: demographics, neurological examina-
tion, and nerve conduction studies (NCS) at baseline and
last visit. Clinical status was rated as 0 = worse,
1 = unchanged, 2 = stabilized after a declining course, or
3 = improved. The electrophysiology data were rated as
0 = worse, 1 = stable, or 2 = improved. Statistical anal-
yses were performed using JMP (version 9.0.2 for Macin-
tosh, from SAS).
Results Seventy percent were males, aged
68.1 ± 12.6 years with neuropathy for 9.8 ± 6.8 years and
follow-up of 4.0 ± 3.2 years. CIDP patients had more
severe neuropathy, and were more likely to receive treat-
ment and to respond. The clinical neuropathy status
remained unchanged in 52.8 % of the MGUSN and 24.2 %
of the CIDP patients, and stabilized in 7.6 % of MGUSN
and 30.3 % of CIDP patients. IgM-MGUSN patients did
not differ from other immunoglobulin subclasses in
response to treatment. The clinical severity and the number
of abnormal NCS parameters were greater in the demye-
linating MGUSN in comparison to the axonal group.
Conclusion MGUSN patients have less severe neuropa-
thy than CIDP patients, but among the MGUSN patients
the severity is greater in the demyelinating and the IgM
groups. MGUSN patients may do well without treatment
and exposure to potential adverse effects.
Keywords Monoclonal gammopathy of undetermined
significance  Chronic inflammatory demyelinating
polyneuropathy  Demyelinating neuropathy  Axonal
neuropathy  Treatment
Introduction
Monoclonal gammopathies are a group of disorders char-
acterized by excessive amounts of serum immunoglobulins
produced by proliferation of a single clone of plasma cells
[1]. Most of the patients have monoclonal gammopathy of
undetermined significance (MGUS) and the rest have sys-
temic diseases such as amyloidosis, multiple myeloma,
osteosclerotic myeloma, lymphoma, Waldenstrom’s mac-
roglobulinemia, POEMS syndrome (polyneuropathy,
organomegaly, endocrinopathy, monoclonal gammopathy
and skin changes) and cryoglobulinemia [2–4]. Ten percent
of patients with idiopathic neuropathy have monoclonal
gammopathy, in contrast to 2.5 % of patients with non-
idiopathic neuropathy suggesting an adverse effect of the
gammopathy on peripheral nerve function [5]. The most
frequent type of immunoglobulin seen with MGUS is IgG,
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and this is in contrast to MGUS-associated neuropathy
(MGUSN) in which the most common type is IgM [3, 6].
MGUSN, classified into IgM and non-IgM associated [7],
is an under diagnosed entity [8]. Chronic inflammatory
demyelinating polyneuropathy (CIDP) is an acquired
symmetrical progressive relapsing sensorimotor neuropa-
thy, and it is reported that 22–30 % of CIDP patients have
MGUS [9–11]. There are varying reports on whether
MGUSN patients are distinguishable from those with CIDP
based on their clinical presentation, electrophysiologic
findings and response to treatment [9–12].
We aimed to determine whether the clinical character-
istics and response to treatment differed in MGUSN, or any
subclass of MGUSN, and CIDP patients.
Research design and methods
Subjects
MGUSN and CIDP subjects attending the Neuromuscular
Clinic at the University Health Network for management of
their immune-mediated polyneuropathy between 1990 and
2013 were evaluated for this study. Our current study
involved the extraction of demographic data, clinical his-
tory, physical examination, laboratory test results and
electrophysiologic data from previously coded charts of
MGUSN and CIDP patients. The Research Ethics Board at
the University Health Network approved the current study
protocol.
All subjects were C18 years of age and had a diagnosis
of CIDP or MGUSN. The 67 patients with CIDP comprised
a cohort matched for age and gender to a CIDP plus dia-
betes patient cohort from a prior study [13]. The CIDP
cohort was selected from a total of 1,900 patients with this
diagnosis and was fully representative of the larger cohort.
The MGUSN cohort included all patients diagnosed with
this disorder in the study period. CIDP was diagnosed
based on the clinical presentation, as judged by a neuro-
muscular expert [VB], and the presence of demyelination
on nerve conduction studies (NCS). CIDP patients fulfilled
the Koski criteria (chronic polyneuropathy progressive for
at least 8 weeks, no serum paraprotein and no genetic
abnormality and either recordable compound muscle action
potentials in at least 75 % of motor nerves and either
abnormal distal latency or abnormal motor conduction
velocity or abnormal F wave latency in [50 % of motor
nerves, OR, symmetric onset or symmetric examination
findings and weakness in all four limbs and proximal
weakness in at least one limb) [14]. Although these criteria
were described later, the CIDP patients in this study ful-
filled these criteria and were matched for age and gender to
an existing cohort of diabetes patients with CIDP. MGUSN
was diagnosed on identification of serum monoclonal
proteins by immunoelectrophoresis after exclusion of
plasma cell dyscrasias (multiple myeloma, osteosclerotic
myeloma, POEM’s syndrome, lymphoma, Waldenstrom’s
macroglobulinemia, amyloidosis) by a hematologist, and
other possible etiologies of peripheral neuropathy with
evaluation of FBS, HbA1c, 2-h GTT, CBC, ESR, anti-GM1
Ganglioside antibodies, LFTs, creatinine, vitamin B12, C3,
C4, rheumatoid factor, anti-DS DNA, VDRL and in some
cases Lyme serology, West Nile virus, CSF protein and cell
count analysis.
Evaluation
All subjects were evaluated by neurological examination,
the validated Toronto Clinical Neuropathy Score (TCNS)
[15, 16], vibration perception threshold (VPT), and med-
ian; peroneal; tibial and sural NCS.
NCS were performed using the Sierra Wave Electro-
myography Instrument (Cadwell Laboratories Inc., Ken-
newick, WA, USA). Age- and height-adjusted NCS
reference values were used, according to the standards of
the Toronto General Hospital (TGH) University Health
Network (UHN) electrophysiologic laboratory.
Nerve conduction studies
Median, peroneal, tibial and sural NCS were performed
using surface stimulating and recording techniques
according to the standards of the Canadian Society of
Clinical Neurophysiologists and the American Association
of Neuromuscular and Electrodiagnostic Medicine [17, 18].
The electromyography instrument measured distal laten-
cies (DL) and amplitudes, and calculated conduction
velocities (CV) automatically. Compound muscle action
potential (CMAP) amplitude was measured as baseline to
peak for the median, peroneal and tibial nerves. For the
sural sensory nerve action potential (SNAP), the amplitude
was measured as baseline to negative peak, or from the
positive peak (if present) to the negative peak. The sural
nerve latency was measured at onset from the initial
deflection from the baseline. The F wave latency was
determined as the minimum reproducible latency obtained
after 10 supra-maximal stimuli were applied.
At each subsequent visit, patients were assessed by
history, clinical examination and repeat NCS. Change in
polyneuropathy status was judged on both clinical and
electrophysiologic grounds. Using the clinical data from
the history and neurological examination at the last visit,
the patients were rated as 0 = worse, 1 = unchanged,
2 = stabilized after declining course, or 3 = improved.
Using the electrophysiology data, the patients were rated as
follows: 0 = worse, 1 = stable or 2 = improved.
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Statistical analyses
Statistical analyses were performed using JMP (version
9.0.2 for Macintosh, from SAS). Demographic data were
expressed as mean ± standard deviation (SD) for normally
distributed data, or median and interquartile range (IQR)
for non-parametric data. Differences in categorical vari-
ables were assessed using the v2, while differences in
continuous variables were assessed using the ANOVA.
p values \0.05 were considered significant.
Results
A total of 123 subjects with a mean age of
68.1 ± 12.6 years were entered into the study. The
demographic profile of the patients is shown in Table 1.
About 70 % of the patients were males in both groups. The
mean duration of neuropathy was 9.8 ± 6.8 years and of
follow-up was 4.0 ± 3.2 years. Neuropathy was more
severe in those with CIDP as demonstrated by the findings
of more abnormality of upper limb reflexes (score of 3 vs 0,
p = 0.005), lower limb reflexes (score of 6 vs 4,
p = 0.009) and also more generalized weakness on clinical
examination with 28.8 % of CIDP patients having gen-
eralized weakness compared with 5.6 % of those with
MGUSN (p = 0.002) although the severity of weakness
was similar (Table 1). However, the percentage of those
able to ambulate without aids did not differ between groups
with about 75 % of patients freely ambulatory. The greater
severity of neuropathy in CIDP patients was evidenced by
more abnormal nerve conduction parameters (median
nerve CMAP amplitude and CV, peroneal nerve CV and
tibial nerve F wave latency) as shown in Table 2. This
table shows only those NCS parameters that were signifi-
cantly different, but all other NCS parameters tended to be
worse in the CIDP group although not reaching a p value of
\0.05 (data not shown). Interestingly, lower limb VPT was
more abnormal in the MGUSN group.
Ninety-two percent of the CIDP patients received
treatment in comparison to 52 % of the MGUSN patients
(p \ 0.0001). Eighty-six percent of the CIDP patients
compared with 26.8 % of MGUSN received intravenous
immunoglobulin (IVIG), 65.7 % CIDP patients versus
21.4 % MGUSN prednisone, 53.7 % CIDP patients versus
8.9 % MGUSN azathioprine, 14.4 % CIDP patients versus
17.9 % MGUSN plasmapheresis, 13.4 % CIDP patients
versus 3.6 % MGUSN mycophenolate mofetil, 3.0 %
CIDP patients versus 5.4 % MGUSN rituximab, 3 % CIDP
patients versus 1.8 % MGUSN cyclophosphamide, 1.5 %
CIDP patients versus 0 MGUSN methotrexate, and 0 CIDP
versus 1.8 % MGUSN chlorambucil. CIDP patients were
more likely to receive IVIG, prednisone, and azathioprine
(p \ 0.0001), and were more likely to respond to IVIG
(p \ 0.0001). There was no difference in the response to
other treatments between the MGUSN and CIDP patients.
The clinical neuropathy status stabilized in 7.6 % of
MGUSN and 30.3 % of CIDP (p = 0.001), and remained
unchanged in more than half of the MGUSN and in 24.2 %
of the CIDP patients (p = 0.001). There was no difference
in the percentage of patients who improved or worsened in
both groups. The NCS remained stable in the majority of
MGUSN and CIDP patients.
In the MGUSN group, 46.4 % had IgM, 39.3 % had IgG,
9 % had IgA, 3.6 % had a combination, and in 1.8 % the
immunoglobulin type was unspecified. Forty-five percent of
the MGUSN had kappa light chains. The patients were clas-
sified according to the heavy chain into two groups: IgM-
MGUSN (n = 26) and non-IgM-MGUSN with IgG, IgA, or a
combination (n = 30). The two groups were the same in age,
gender, duration of neuropathy and the distribution of light
chains (kappa or lambda). Anti-MAG antibodies were seen in
30.8 % of IgM-MGUSN patients and in none of the non-IgM-
MGUSN patients (p = 0.001). IgM-MGUSN patients had
more severe neuropathy as demonstrated by higher VPT
values in both upper and lower limbs and a tendency to more
abnormal NCS parameters, significantly so for the median and
peroneal nerve distal motor latencies. There was no difference
between the two groups in distribution of weakness. About
the patients were treated in each group. There was no differ-
ence in the use of azathioprine, mycophenolate mofetil, rit-
uximab, cyclophosphamide, methotrexate, IVIG or
plasmapheresis between the two groups. Prednisone was used
more commonly in non-IgM-MGUSN patients (p = 0.025).
There was no difference in the response to any of the treat-
ments. The clinical neuropathy status remained unchanged in
about half of both groups. The NCS remained stable in about
two-thirds of the patients in both groups. However, there was a
trend towards more clinical and electrophysiologic improve-
ment and less worsening in IgM-MGUSN patients. When
comparing IgM-MGUSN patients to CIDP patients, there was
no difference in severity (comparable TCNS and NCS with
the exception of longer tibial nerve F wave latencies in the
CIDP group), but VPT was higher in those with IgM para-
proteins. Comparing non-IgM-MGUSN to CIDP patients,
CIDP patients had more severe neuropathy as demonstrated
by both TCNS and NCS.
We stratified the MGUSN patients into demyelinating
(n = 29) and axonal (n = 27) forms as shown in Table 3.
We found that those classified as demyelinating had more
lambda light chains (14 vs 5, p = 0.017), had all the anti-
MAG antibody-positive patients (8 vs 0, p = 0.005) and
had more severe polyneuropathy as shown by the VPT,
TCNS data and the number of abnormal NCS parameters
(Table 3). There was no difference in age, gender or
duration of neuropathy.
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Discussion
We examined our cohort of MGUSN patients and com-
pared them to an existing cohort of CIDP patients to
determine whether the clinical characteristics and response
to treatment differed between the groups or in subclasses of
MGUSN.
The age, gender and the duration of the polyneuropathy
did not differ between the two groups in this study, similar
to findings in a previous report [10]. However, other
authors found that CIDP-MGUS patients were more likely
to be older males in comparison to idiopathic CIDP (CIDP-
I) [11, 12] .
In our cohort, CIDP patients had more severe neuropa-
thy based on both clinical and electrodiagnostic measures.
These differences were most apparent between non-IGM-
MGUSN and CIDP patients (data not shown) than between
IgM-MGUSN and CIDP patients. Several studies com-
pared CIDP patients with and without MGUS [9–12], but
none—up to our knowledge—compared purely axonal
MGUSN to CIDP or subclasses of MGUSN to CIDP. Our
results are similar to those of Simmons et al. [9] who found
less severe weakness and a more indolent course in CIDP-
MGUS. However, they contrast with Gorson et al. [10]
who found that CIDP-MGUS patients did not have a more
indolent course despite the fact that weakness was less
common in this group, and Bromberg et al. who found that
CIDP-MGUS cannot be distinguished from CIDP-I on the
Table 1 Demographic profile of 123 patients with monoclonal
gammopathy of undetermined significance-associated neuropathy
(MGUSN) (56) and chronic inflammatory demyelinating polyneu-
ropathy (CIDP) (67)
Parameter MGUSN CIDP p valuea
Age (years), mean ± SD 70 ± 11.5 66.5 ± 13.4 0.124
Age range (years) (45–90) (36–90) –
Gender male (%) 70 72 0.808
Duration of follow-up (years),
mean ± SD




9.9 ± 6.1 9.7 ± 7.4 0.920
TCNS_symptomsb, Median
(IQR)
3 (2–4) 4 (3–5) 0.181
TCNS_sensoryc, Median
(IQR)
4 (2–5) 4 (2–4) 0.496
TCNS_deep tendon reflexesd,
Median (IQR)
4 (1.25–6) 6 (4–8) 0.009
TCNS_totale, Median (IQR) 11 (7–14) 13 (8–16) 0.053
Weakness on examf, n (%) 22 (39.3) 34 (50.8) 0.203
Weakness proximalf, n (%) 3 (5.4) 3 (4.5) 1
Weakness distalf, n (%) 14 (25) 16 (23.9) 0.886
Weakness generalizedf, n (%) 3 (5.6) 19 (28.8) 0.002
Gait abnormal, n (%) 30 (53.6) 34 (50.8) 0.755
Independent walking (%) 78.6 74.6 0.61
Treated patients, n (%) 29 (51.8) 62 (92.5) \0.0001
IVIG, n (%) 15 (26.8) 58 (86.6) \0.0001
Prednisone, n (%) 12 (21.4) 44 (65.7) \0.0001
Plasmapheresis, n (%) 10 (17.9) 10 (14.4) 0.661
Azathioprine, n (%) 5 (8.9) 36 (53.7) \0.0001
Mycophenolate mofetil, n (%) 2 (3.6) 9 (13.4) 0.065
Rituximab, n (%) 3 (5.4) 2 (3) 0.659
Cyclophosphamide, n (%) 1 (1.8) 2 (3.0) 1
Methotrexate, n (%) 0 (0) 1 (1.5) 1
Chlorambucil, n (%) 1 (1.8) 0 (0) 0.459
IVIG intravenous immunoglobulin
a p values \0.05 are considered significant
b Toronto clinical neuropathy score_symptoms: present = 1;
absent = 0 (0–6)
c Toronto clinical neuropathy score_sensory: abnormal = 1; nor-
mal = 0 (0–5)
d Toronto clinical neuropathy score_deep tendon reflexes:
absent = 2; reduced = 1; normal = 0 (0–8)
e Toronto clinical neuropathy score_total: normal = 0 to maximum
of 19
f Weakness determined by Medical Research Council (MRC) grading
of muscles
Table 2 Quantitative sensory threshold and nerve conduction testing
in 123 patients with monoclonal gammopathy of undetermined sig-
nificance-associated neuropathy (MGUSN) (56) and chronic inflam-
matory demyelinating polyneuropathy (CIDP) (67)
Parameter MGUSNa CIDPa p valueb




























































VPT vibration perception threshold, CMAP compound muscle action
potential amplitude, CV conduction velocity
a Values are shown as means ± standard deviations (range)
b p values \0.05 are considered significant
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basis of NCS [11]. In our cohort, we found differences but
particular cut-off values for individual patients would
require a different study. About 90 % of the CIDP patients
in comparison to 50 % of the MGUSN patients in our
cohort were treated, likely due to greater severity of the
disease in the CIDP patients warranting treatment. More
CIDP patients were stabilized compared to MGUSN
patients, but there were no differences in patients catego-
rized as improving or worsening. Because of the uneven
number of treated patients in both groups, we examined the
outcome of the treated MGUSN patients only and com-
pared it to the treated CIDP patients. We found the post
treatment clinical and electrophysiologic status to be the
same in both groups, except that more treated CIDP
patients stabilized in comparison to treated MGUSN
patients (32.8 versus 10.3 %, respectively, p = 0.037). The
CIDP patients had more responders to IVIG treatment
when compared to all MGUSN patients combined or when
compared to those with IgM- or non-IGM-MGUSN
patients, and had more responders to plasmapheresis when
compared to non-IgM-MGUSN patients in contrast to an
earlier report [10]. In a long-term follow-up by Simmons
et al. [12] in which 90 % of the CIDP-I and 80 % of the
CIDP-MGUS patients were treated, CIDP-MGUS had
more functional impairment at the end of the follow-up
period, but we do not find a similar outcome in this study.
It is thought that MGUSN patients have demyelinating
disease and that axonal features are secondary [19], but
Notermans et al. [20] found that 40 % of MGUSN are
purely axonal. Filostso et al. [8] detected pure axonal
findings in 46 % of IgG and 20 % of IgM-MGUSN
patients. In our cohort, about 48 % of the MGUSN patients
had primarily axonal neuropathy and 52 % were primarily
demyelinating. The lambda paraprotein was observed more
frequently in the demyelinating category and all anti-MAG
antibody-positive patients fell into this group, although the
prevalence of anti-MAG was less than described by Filosto
et al. [8]. Although there were no differences in the gender,
age of onset or duration of the peripheral neuropathy, the
clinical severity and the number of abnormal NCS
parameters were greater in the demyelinating group as was
the percentage of treated patients (70 % of the demyelin-
ating vs 30 % of the axonal, p = 0.001). In our cohort,
axonal and demyelinating MGUSN patients responded
similarly to treatment in contrast to the experience of
Gorson et al. [19].
As reported previously [21–23], there were no differ-
ences between subclasses of MGUSN (IgM versus others)
with respect to duration of peripheral neuropathy, age,
gender or presenting symptoms, or signs. However, others
found that IgM-MGUSN patients are more likely to have
sensory dysfunction, progressive course, and a more severe
predominantly demyelinating polyneuropathy in compari-
son to other subclasses [20–22, 24, 25]. On NCS we found
that IgM-MGUSN group had longer distal motor latencies
in the upper and lower limbs similar to the findings of
Suarez and Kelly [24]. There was no difference in response
to treatment between the two groups as reported previously
Table 3 Patients with monoclonal gammopathy of undetermined
significance-associated neuropathy (MGUSN) classified as demye-
linating or axonal polyneuropathy
Parameter Demyelinating Axonal p valuea
Gender male (%) 69 70.4 0.91
Age (years), mean ± SD 70 ± 11.4 70 ± 11.7 0.982
Duration of follow-up in
years, mean ± SD
3.2 ± 2.7 3.3 ± 3.5 0.913
IgG, n (%) 9 (31) 13 (48.2) 0.189
IgM, n (%) 17 (58.6) 9 (33.3) 0.057
IgA, n (%) 2 (6.9) 3 (11.1) 0.58
IgM and IgG, n (%) 0 1 (3.7) 0.482
IgG and IgA, n (%) 0 1 (3.7) 0.482
Unspecified, n (%) 1 (3.5) 0 1
Lambda, n (%) 14 (48.3) 5 (18.5) 0.017
Kappa, n (%) 10 (34.5) 15 (55.6) 0.112
Lambda and kappa, n (%) 1 (3.5) 5 (18.5) 0.096
Unspecified, n (%) 4 (13.8) 2 (7.4) 0.671
Anti-MAG, n (%) 8 (27.6) 0 0.005
VPT-right upper limb,
mean ± SD
7.2 ± 4.5 5.1 ± 1.7 0.343
VPT-left upper limb,
mean ± SD
7.2 ± 4.5 5.0 ± 1.7 0.029
VPT-right lower limb,
mean ± SD
38.4 ± 14.6 24.0 ± 13.7 0.001
VPT-left lower limb,
mean ± SD
37.4 ± 14.5 23.9 ± 14.0 0.001
TCNS-symptomsb,
mean ± SD
3.7 ± 1.4 3.0 ± 1.3 0.059
TCNS-sensoryc,
mean ± SD
3.8 ± 1.3 2.8 ± 1.9 0.026
TCNS-deep tendon
reflexesd, mean ± SD
4.7 ± 2.8 3.1 ± 2.6 0.037
TCNS-totale, mean ± SD 12.1 ± 3.8 8.9 ± 4.1 0.004
Number of abnormal nerve
conduction studies
parameters
8.1 ± 2.5 5.7 ± 3.5 0.005
MAG myelin associated glycoprotein, VPT vibration perception
threshold
a p values \0.05 are considered significant
b Toronto clinical neuropathy score_symptoms: present = 1;
absent = 0 (0–6)
c Toronto clinical neuropathy score_sensory: abnormal = 1; nor-
mal = 0 (0–5)
d Toronto clinical neuropathy score_deep tendon reflexes:
absent = 2; reduced = 1; normal = 0 (0–8)
e Toronto clinical neuropathy score_total: normal = 0 to maximum
of 19
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by Simovic et al. [21], this is in contrast to Yeung et al.
[23] who concluded that IgG- and IgA-MGUSN patients
are more likely to respond to treatment than IgM-MGUSN
patients.
Our results support the concept that CIDP patients differ
from those with MGUSN. The MGUSN clinical phenotype
shows milder disease that leads less frequently to treatment
although IgM-MGUSN patients had more severe disease
within the MGUSN group. Further, demyelinating
MGUSN patients had more severe clinical disease with
significantly more abnormal NCS parameters in compari-
son to axonal MGUSN. As well, treatment response rate
appears to be lower in MGUSN patients, adding some
validity to the choice to defer treatment in these patients.
Given the potential adverse effects of most immunosup-
pressive treatments, and the expense and limited access to
immunomodulation treatments, it is important to determine
the best therapeutic choices for patients with immune-
mediated polyneuropathies. Our study suggests that those
with MGUSN may do well without treatment in many
cases and patients can avoid exposure to adverse effects
and high costs. Even with treatment, it should be noted that
only few patients stabilized or improved.
The limitations of our study are that it is a retrospective
review with inherent difficulties in standardized evaluations,
treatments, and data collection; however, all reports comparing
MGUSN to CIDP—up to our knowledge—have been retro-
spective to date [9–12, 26]. Also, the CIDP cohort was selected
for a prior study for age and gender factors, and not all patients
diagnosed with CIDP in our clinic within the timeframe of the
study were included and thus the results may not be general-
izable to all CIDP patients. Some novel and improved mea-
sures in inflammatory neuropathies such as the Rasch overall
disability scale [27] and the overall neuropathy limitation scale
(ONLS) [28] were not available when these patients were
evaluated and their use might have provided better insight into
patient outcomes. In addition, the TCNS is not a linear scale
and sensitivity to change may be limited. Finally, MGUSN
patients had milder disease with a floor effect for improvement.
Further, although we defined the demyelinating categories on
the basis of NCS, we do not have morphological confirmation
of the underlying pathology. Despite these considerations, our
study suggests that MGUSN differs from CIDP both in clinical
severity and response to treatment. MGUSN is a heterogenous
disorder and alone it shows variability between IgM and non-
IgM forms. A multi-center prospective natural history and
intervention study might allow better determination of which
MGUSN patients to treat.
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